This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Can Monsanto Hold its Momentum with 2Q Earnings?

Stocks in this article: MON

What's not to like? I get it -- the stock is not cheap when compared to DuPont and Syngenta. But it's not as if the valuation is undeserved, especially given a recent 7% improvement in operating margin, which (by the way) is twice that of DuPont and 7 percentage points better than Syngenta. Let's have some perspective.

Expectations for the Second Quarter

After a dominant Q1 performance, I suppose you can say Monsanto has its own tough act to follow. The company will report second-quarter earnings on Wednesday and the Street is eager to see if management can carry the strong momentum from Q1. Analysts are expecting $2.56 in earnings per share on revenue of $5.27 billion, which, relative to Q1's performance seems a bit soft.

It's worth noting here that in the year-ago quarter; Monsanto posted a net income of $1.21 billion, or $2.24 per share on revenue of $4.75 billion. Essentially, the Street is looking for 11% year-over-year revenue growth and 14% growth in earnings.

Considering that Q1 revenue arrived up 21% -- beating estimates by more than 10% -- a similar performance could push revenue in the high range of $5.8 billion to $6 billion. Investors shouldn't be surprised by an "upside surprise." And for the momentum to truly continue, management has to deliver the goods on the high end to shut the bears up for good.

The Street will also be paying attention to what management says about the $1.7 billion royalty payments Monsanto won from DuPont. The two companies reached a settlement last month in what has been an on-going patent lawsuit over technology used in genetically modified soybean and corn seeds.

DuPont agreed to pay more than $1.7 billion for the next decade for soybeans that are resistant to Roundup weed killer, which is manufactured by Monsanto. This is important because it will impact Monsanto's long-term earnings (2014 to 2017) by as much as 30 cents per share according to analysts.

Bottom Line

I'm always hesitant to recommend a stock that is sitting at (or near) its 52-week high. However, Monsanto is in an interesting situation. While growth is not an issue for this company, this is not a typical "tech-type" play, either. That is to say, Monsanto is more of a long-term investment /> . As such, the stock being at a 52-week high is not a concern.

While it's also true that the stock is not cheap at a P/E of 25, Monsanto is also trading at just 20-times forward fiscal 2014 earnings. And given that royalty payments from DuPont will start kicking in, which raises EPS by as much as 30 cents a share, patient investors can still do very well with Monsanto.

At the time of publication, the author held no position in any of the stocks mentioned.

Richard Saintvilus is a private investor with an information technology and engineering background and the founder and producer of the investor Web site Saint's Sense. He has been investing and trading for over 15 years. He employs conservative strategies in assessing equities and appraising value while minimizing downside risk. His decisions are based in part on management, growth prospects, return on equity and price-to-earnings as well as macroeconomic factors. He is an investor who seeks opportunities whether on the long or short side and believes in changing positions as information changes.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs